SHANGHAI, Oct. 16, 2015 /PRNewswire/ -- WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), a leading open-access R&D
capability and technology platform company serving the
pharmaceutical, biotechnology, and medical device industries, today
announced that it has received the 2015 Asian CRO Company of the
Year award from Frost & Sullivan, a leading business research
and consulting firm. The award is part of the Frost &
Sullivan Asia Pacific Best Practices Awards series, recognizing
companies in Asia Pacific that
demonstrate outstanding achievement and superior performance in
areas such as leadership, technological innovation, customer
service, and strategic product development.
WuXi is being recognized for its strong performance and
continued investments in the Asia
Pacific region. Frost & Sullivan cited WuXi's local
market knowledge, world-class facilities, reputation for high
quality, rapid turnaround times, comprehensive customer support,
and strong commitment to the highest global regulatory
standards.
"We thank Frost & Sullivan for recognizing WuXi's diligent
efforts in providing best-in-class service to our clients to help
them accelerate healthcare product development with cost efficiency
and quality," said Dr. Ge Li,
chairman and CEO of WuXi PharmaTech. "Combining our
open-access enabling platform with local market expertise, we are
working together with our customers and partners to bring better
medicines faster to patients in Asia
Pacific and around the world."
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States.
As a research-driven and customer-focused company, WuXi PharmaTech
provides a broad and integrated portfolio of services throughout
the drug and medical device R&D process. WuXi is also
building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. WuXi
PharmaTech's services are designed to assist its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. WuXi PharmaTech's operating subsidiaries are
known as WuXi AppTec. For more information, please visit:
http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for
investors)
LaVoieHealthScience
+1-617-374-8800 x109
+1 617-792-2459
ir@wuxiapptec.com
Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
pr@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-receives-2015-asian-cro-company-of-the-year-award-from-frost--sullivan-300157577.html
SOURCE WuXi PharmaTech (Cayman) Inc.